Company Overview - Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over thirty years of high-quality production history [1][2] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - For Q1 2025, the company reported revenue of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% [2] - The sales gross margin for the same period was 29.26% [2] Market Position - As of August 19, the company's stock closed at 8.06 yuan, with a PE ratio of 45.69, compared to the industry average of 59.49 and the industry median of 40.19 [1][2] - The total market capitalization of Huangshan Capsule is 2.411 billion yuan [1] Shareholder Information - As of March 31, 2025, the number of shareholders is 18,378, a decrease of 26 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Core Insights - Huangshan Capsule's stock closed at 8.18 yuan, up 1.11%, with a rolling PE ratio of 46.37 times and a total market capitalization of 2.447 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 55.70 times and a median of 39.08 times, placing Huangshan Capsule at the 84th position in the industry ranking [1] - As of the first quarter of 2025, only one institution holds shares in Huangshan Capsule, with a total of 18,000 shares valued at 0.00 billion yuan [1] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules [1] - The company is one of the earliest manufacturers of medicinal hollow capsules in China, boasting over 30 years of high-quality production history [1] - Huangshan Capsule has a strong reputation in the medicinal hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In the first quarter of 2025, the company reported an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% [2] - The sales gross margin for the company stands at 29.26% [2] Industry Comparison - Huangshan Capsule's PE (TTM) is 46.37, compared to the industry average of 55.70 and the industry median of 39.08 [2] - The company’s market capitalization is 2.447 billion yuan, while the industry average market capitalization is 11.731 billion yuan [2]

Core Viewpoint - Huangshan Capsule's stock closed at 8.19 yuan on August 4, with a 1.74% increase, and a rolling PE ratio of 46.43, marking a new low in 373 days, with a total market value of 2.45 billion yuan [1] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In the latest quarterly report for Q1 2025, the company achieved an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90%, with a gross profit margin of 29.26% [2] Market Position - Huangshan Capsule's PE ratio of 46.43 is below the industry average of 54.31 and the industry median of 38.11, ranking 84th in the medical device sector [1][2] - The company’s market value stands at 2.45 billion yuan, compared to the industry average market value of 11.617 billion yuan [2] Capital Flow - On August 4, the net inflow of main funds into Huangshan Capsule was 764,500 yuan, although the overall trend over the past five days showed a net outflow of 4.3336 million yuan [1]

Company Overview - Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, with over 30 years of high-quality production history [1] - The company is one of the earliest manufacturers of pharmaceutical hollow capsules in China and has a high reputation in the industry [1] Financial Performance - For Q1 2025, the company reported operating revenue of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, up 22.90% year-on-year [2] - The sales gross margin for the same period was 29.26% [2] Market Position - The company's current price-to-earnings (PE) ratio is 44.84, compared to the industry average of 54.89 and the industry median of 37.06 [2] - Huangshan Capsule's total market capitalization is 2.366 billion yuan [1] Industry Context - The medical device industry, where Huangshan Capsule operates, has an average PE ratio of 54.89 and a median of 37.06 [2] - Huangshan Capsule ranks 83rd in terms of PE ratio within its industry [1] Capital Flow - On July 31, the company experienced a net outflow of main funds amounting to 2.725 million yuan, with a total outflow of 3.7357 million yuan over the past five days [1]

Company Overview - Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1][2] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - For Q1 2025, the company reported revenue of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% [2] - The sales gross margin for the same period was 29.26% [2] Market Position - As of July 16, the company's stock closed at 7.76 yuan, with a PE ratio of 43.99, marking a new low in 353 days, and a total market capitalization of 2.321 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 51.87, with a median of 37.48, placing Huangshan Capsule at the 84th position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders for Huangshan Capsule was 18,378, a decrease of 26 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

7月7日，黄山胶囊今日收盘7.57元，上涨1.47%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到42.91倍，创346天以来新低，总市值22.64亿元。 安徽黄山胶囊股份有限公司的主营业务是明胶空心胶囊和肠溶明胶空心胶囊的研发、生产与销售。公司 的主要产品是明胶空心胶囊、肠溶明胶空心胶囊、羟丙甲纤维素空心胶囊、普鲁兰多糖空心胶囊。公司 是中国最早的药用空心胶囊生产企业之一，拥有三十多年高品质药用空心胶囊生产历史。在药用空心胶 囊行业，公司具有较高的知名度，现为中国医药包装协会突出贡献奖成员单位、药用空心胶囊专业委员 会副主任单位之一。公司的商标被评为安徽省著名商标，"旌川"牌药用空心胶囊获"安徽名牌产品"称 号。"旌川"牌明胶空心胶囊和肠溶明胶空心胶囊荣获"中国化学制药行业药用辅料优秀产品品牌"。 最新一期业绩显示，2025年一季报，公司实现营业收入1.19亿元，同比0.53%；净利润1883.70万元，同 比22.90%，销售毛利率29.26%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13黄山胶囊42.9145.972.4222.64亿行业平均 51.4249.164.50 ...

Core Viewpoint - Huangshan Capsule's stock closed at 7.23 yuan on June 24, with a 2.55% increase, resulting in a rolling PE ratio of 40.98 times and a total market value of 2.162 billion yuan [1] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In the first quarter of 2025, the company reported an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% with a sales gross margin of 29.26% [2] - The company's PE ratio (TTM) stands at 40.98, while the industry average is 49.12, and the industry median is 36.07 [2] Market Position - Huangshan Capsule ranks 84th in the industry based on PE ratio, with the medical device industry average PE at 49.12 and the median at 36.07 [1][2] - The company has received several accolades, including the "Anhui Famous Brand Product" for its "Jingchuan" brand gelatin hollow capsules and recognition as an excellent product brand in the pharmaceutical excipients sector [1]

Core Viewpoint - Huangshan Capsule's stock closed at 7.41 yuan, up 1.51%, with a rolling PE ratio of 42.00, marking a new low in 325 days, and a total market value of 2.216 billion yuan [1][2] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In Q1 2025, the company achieved an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, up 22.90% year-on-year, with a gross profit margin of 29.26% [2] Market Position - Huangshan Capsule ranks 84th in the industry based on PE ratio, with the average PE ratio for the medical device industry at 50.64 and the median at 37.05 [2] - The average market value of the industry is 10.91 billion yuan, while Huangshan Capsule's market value is 2.216 billion yuan [2] Shareholder Information - As of March 31, 2025, Huangshan Capsule had 18,378 shareholders, a decrease of 26 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

6月3日，黄山胶囊今日收盘7.26元，上涨1.40%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到41.15倍，创321天以来新低，总市值21.71亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均50.80倍，行业中值36.71倍，黄山胶囊排 名第84位。 资金流向方面，6月3日，黄山胶囊主力资金净流入441.15万元，近5日总体呈流入状态，5日共流入 282.42万元。 安徽黄山胶囊股份有限公司的主营业务是明胶空心胶囊和肠溶明胶空心胶囊的研发、生产与销售。公司 的主要产品是明胶空心胶囊、肠溶明胶空心胶囊、羟丙甲纤维素空心胶囊、普鲁兰多糖空心胶囊。公司 是中国最早的药用空心胶囊生产企业之一，拥有三十多年高品质药用空心胶囊生产历史。在药用空心胶 囊行业，公司具有较高的知名度，现为中国医药包装协会突出贡献奖成员单位、药用空心胶囊专业委员 会副主任单位之一。公司的商标被评为安徽省著名商标，"旌川"牌药用空心胶囊获"安徽名牌产品"称 号。"旌川"牌明胶空心胶囊和肠溶明胶空心胶囊荣获"中国化学制药行业药用辅料优秀产品品牌"。 最新一期业绩显示，2025年一季报，公司实现营业收入1.19亿元 ...

Core Viewpoint - Huangshan Capsule's stock closed at 7.21 yuan, up 1.12%, with a rolling PE ratio of 40.87, marking a new low in 103 days, and a total market value of 2.156 billion yuan [1][2] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In Q1 2025, the company achieved an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, up 22.90% year-on-year, with a gross profit margin of 29.26% [2] Market Position - Huangshan Capsule ranks 84th in the medical device industry based on PE ratio, with the industry average at 49.51 and the median at 36.17 [1][2] - The average PE ratio for the industry is significantly higher than Huangshan Capsule's current PE ratio, indicating potential undervaluation [2]